Envisia Therapeutics

Industry

  • Biotechnology
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
See more in Biomedtracker

Latest on Envisia Therapeutics

In Vivo

Deals Shaping The Medical Industry, November 2017

 
• By Beth Allan, Deanna Kamienski, Amanda Micklus, Steven Muntner, and Maureen Riordan

IN VITRO DIAGNOSTICS Financings CareDx Inc. Molecular diagnostics firm CareDx Inc. netted $18.8mm through the follow-on public offering of 4.99mm common shares (including full exercise of the over

Scrip

Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan

 
• By Joseph Haas, Kevin Grogan, and Mandy Jackson

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

In Vivo

Execs On The Move, May 2015

 
• By Regina Paleski

New At The Helm Company Changes AVNI , Yuval, MD To: Beta-O2 Technologies Ltd. , CEO (March) From: Giza VC, Partner Phone: +972 3 918 0700 BECKMAN , Richard, MD To: Unilife Corp. , SVP, CM

Scrip

Start-Up Execs On The Move, May 2015

 
• By Regina Paleski

Start-Up Execs Allena Pharmaceuticals Inc. Louis Brenner, MD To: COO (April) From: SVP, CMO, Idera Pharmaceuticals Phone: 215-791-0105 Aimmune Therapeutics Inc. Mary Rozenman, PhD To: SVP,